Dare Bioscience (DARE) Income from Continuing Operations (2016 - 2026)
Dare Bioscience's (DARE) quarterly Income from Continuing Operations came in at 1636994.0 in Q4 2025, up 69.4% YoY from 966372.59 in Q4 2024, and up 71.69% on a QoQ basis from 5783148.0 in Q3 2025.
Dare Bioscience (DARE) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 10 years of Income from Continuing Operations data on file, last reported at 1636994.0 in Q4 2025.
- Quarterly Income from Continuing Operations rose 69.4% year-over-year to 1636994.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 20371439.0 (up 15.04% YoY) and the FY2025 annual result came in at 127295334.0, up 8.41% from the prior year.
- Income from Continuing Operations grew to 1636994.0 in Q4 2025, from 5783148.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 304322.0 in Q2 2022 to a low of 16299567.0 in Q4 2022.
- A 5-year average of 7363725.55 and a median of 7398580.5 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 103.28% — and 2023, when it slumped 3088.4%.
- Tracing DARE's Income from Continuing Operations over 5 years: stood at 9662115.0 in 2021, then slumped by 68.7% to 16299567.0 in 2022, then jumped by 65.82% to 5571460.0 in 2023, then rose by 3.99% to 5348909.0 in 2024, then soared by 69.4% to 1636994.0 in 2025.
- The last three Income from Continuing Operations figures came in at 1636994.0 (Q4 2025), 5783148.0 (Q3 2025), and 5947800.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 | -2.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.89 Mn |
| Dec 31, 2025 | -1.64 Mn |
| Sep 30, 2025 | -5.78 Mn |
| Jun 30, 2025 | -5.95 Mn |
| Mar 31, 2025 | -7.00 Mn |
| Dec 31, 2024 | -5.35 Mn |
| Sep 30, 2024 | -4.91 Mn |
| Jun 30, 2024 | -7.58 Mn |
| Mar 31, 2024 | -6.14 Mn |
| Dec 31, 2023 | -5.57 Mn |
| Sep 30, 2023 | -8.50 Mn |
| Jun 30, 2023 | -9.09 Mn |
| Mar 31, 2023 | -8.49 Mn |
| Dec 31, 2022 | -16.30 Mn |
| Sep 30, 2022 | -7.22 Mn |
| Jun 30, 2022 | 304,322.00 |
| Mar 31, 2022 | -8.52 Mn |
| Dec 31, 2021 | -9.66 Mn |
| Sep 30, 2021 | -12.79 Mn |
| Jun 30, 2021 | -9.28 Mn |